Coverage window: September 21-27, 2026.
This week brought two unusually concrete forms of follow-through. A corneal cell-therapy team treated two eyes for a second time after their first cultured endothelial grafts lost function years later. A new infant trial will test whether intranasal marrow-derived stromal cells can change neurodevelopment after hypoxic-ischemic brain injury.
Manufacturing and measurement moved too. Chemically defined microgels carried iPSCs from expansion into cardiac and retinal differentiation, while human serum albumin preserved more viable stromal cells through a simulated infusion line. A commercial MSC product gained an additional lot-release assay. Two CNS programs entered the issue at an earlier stage: an organoid-based exosome profiling system for Alzheimer’s disease and a newly posted ALS trial of a cell-derived protein complex.
1. A second corneal cell injection restores an endothelial layer in two eyes
Full analysis: A Second Corneal Cell Injection After the First Graft Fades
Primary source: complete *Cornea* article
Two participants from the first human study of cultured corneal endothelial cells returned after their prototype grafts lost function. One original graft had kept the cornea clear for about four years, the other for about nine. Both eyes received one million mature cultured endothelial cells with a Rho kinase inhibitor in 2024.
At one year, central corneal thickness changed from 786 to 572 micrometers in one eye and from 688 to 523 micrometers in the other. Endothelial cell density reached 2,292 and 2,552 cells per square millimeter. Neither case developed graft rejection, elevated intraocular pressure, or anterior uveitis during the reported period.
The intervention included surgical polishing of the recipient surface, three hours of face-down positioning, and corticosteroid treatment. Two cases establish technical feasibility. They cannot determine a general success rate, compare retreatment with tissue keratoplasty, or show how long the second cell layer will last.
2. A randomized infant trial will test intranasal stromal cells after brain injury
Primary source: ClinicalTrials.gov record NCT07831746
UMC Utrecht posted iSTOP-CP on September 21. The double-blind, placebo-controlled phase 2/3 study plans to enroll 162 infants with MRI-confirmed hypoxic-ischemic brain injury caused by perinatal arterial ischemic stroke or perinatal asphyxia. Participants will receive one intranasal dose of allogeneic bone-marrow-derived mesenchymal stromal cells or placebo within seven days of birth.
The primary endpoint is the Bayley-IV-NL motor composite score at about 24 months. Secondary measures include cognition, sensorineural disability, safety, neuroregenerative imaging, family quality of life, and health-economic outcomes. The trial is listed as not yet recruiting and has no posted results.
This design moves beyond the ten-infant feasibility study cited in the registry entry by adding masking, a control group, and longer developmental follow-up. The record provides the plan, not evidence that intranasal cells reach injured brain tissue or improve cerebral-palsy outcomes.
3. Microgels carry iPSCs from expansion into automated organoid production
Full analysis: Microgels Give iPSCs a Scaffold They Can Build Around
Primary sources: September 23 journal publication and complete earlier manuscript
Researchers made uniform PEG microgels, coupled recombinant vitronectin to their surfaces, and mixed them with iPSCs. The cells adhered around the particles and pulled them into porous three-dimensional constructs. They could expand first and then undergo directed differentiation without leaving the scaffold.
Larger constructs reached roughly three millimeters and supported cardiac differentiation with coordinated beating. A smaller workflow used automated liquid handling in low-volume 384-well plates; the paper reports a run of 160 constructs. Retinal protocols produced progenitor and photoreceptor-associated markers as a second tissue example.
The new event is the peer-reviewed publication. Detailed numerical analysis relies on the complete 2025 preprint because the publisher's final text was closed to the routes checked. The platform has yet to show multi-line, multi-batch screening performance, mature tissue function, or suitability for transplantation.
4. Ultrasound increases organoid exosome output for an Alzheimer’s profiling assay
Primary source: complete *Science Advances* article
Human iPSC-derived cortical organoids were exposed to low-intensity pulsed ultrasound, and their extracellular vesicles were captured on gold-coated zinc oxide nanowires for label-free surface-enhanced Raman spectroscopy. Under the selected 70-kPa, ten-minute condition, exosome-associated signal increased about 2.3-fold.
The system separated exosome spectra from APOE3 and APOE4 organoid models more clearly after stimulation, with a PCA silhouette score rising from 0.37 to 0.50. The authors also reported a reproducible signal associated with amyloid-beta exposure. Their statistical detection limit was extrapolated; the experimentally supported quantitation level was 10,000 particles per milliliter.
This is an organoid and sensor study. Serum from one participant served as a matrix check, leaving clinical classification performance untested. Ultrasound also activated stress-related pathways, so increased vesicle output cannot be assumed to preserve an unchanged biological sample.
5. Albumin keeps more stromal cells in suspension through an infusion line
Primary source: article record and abstract
A simulated syringe-pump-catheter workflow tested clinical-grade adipose-derived mesenchymal stromal cells in three crystalloid solutions with or without human serum albumin. The abstract reports viable-cell recovery of 99.8% with albumin and 85.1% without it immediately after infusion. After an overnight hold, viability was 87.8% versus 50.5%.
Image analysis found more single cells and less debris with albumin, without an increase in aggregate burden. The result makes final formulation part of dose delivery: a vial count does not guarantee that the same number of viable cells exits the catheter.
The experiment simulated administration and short-term holding. It did not treat patients or establish that a higher delivered viable-cell count improves an outcome. The complete article body was unavailable through the publisher and alternate legitimate routes, so this capsule stays within the abstract.
6. Ryoncil adds a T-cell proliferation assay to commercial lot release
Primary sources: Mesoblast filing and FDA product page
Mesoblast reported on September 24 that FDA approved its T-cell Proliferation Inhibition BioAssay for release and stability monitoring of new commercial Ryoncil lots. The assay measures inhibition of T-cell proliferation and joins existing tests for IL-2 receptor alpha inhibition and cell adhesion and proliferation.
Potency assays matter because an MSC product has multiple biological activities and can change as manufacturing processes or facilities evolve. The additional assay gives the release matrix another view of immune-modulatory function.
The announcement comes from the manufacturer through a securities filing. It contains no new patient outcomes, lot-comparison results, or independent assay performance data. FDA's public product page confirms Ryoncil's approved indication; the specific assay change is reported by Mesoblast.
7. A phase 2 ALS trial will test a cell-derived protein complex
Primary source: ClinicalTrials.gov record NCT07833618
A new record posted September 22 describes a randomized, double-blind, placebo-controlled phase 2 study of ALT001 in 150 people with amyotrophic lateral sclerosis. Participants are planned to receive intravenous doses of 1.0 or 2.0 micrograms per kilogram, or placebo, through a 24-week blinded period. Change in ALSFRS-R is the primary endpoint.
ALT001 is described as an allogeneic unrelated umbilical-cord MSC-derived protein complex. It is a cell-derived drug rather than a live-cell infusion. The protocol also includes respiratory, function-and-survival, quality-of-life, biomarker, immunogenicity, and safety measures, followed by an open-label extension.
The record lists the trial as not yet recruiting at one site in China, with no results. Its size and control design make it worth tracking, while the registry alone does not establish composition, mechanism, target engagement, or clinical benefit.